Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Metabolic Manipulation of Tc1 CD8 Cells for Enhanced Immunotherapy Against Tumour Hypoxia

EF 2023-24

Résumé
Adoptive Cell Therapy (ACT) is a promising frontier in cancer treatment, harnessing the patient's own T cells for personalized therapeutic interventions. However, challenges persist, such as low oxygen in the tumour microenviroment prompting the need for interventions to improve outcomes. Tc1 CD8 cells, activated during viral or cancer related immune responses, have strong anti-tumor traits which can be crucial for ACT success. Tumour hypoxia, caused by poor blood supply and rapid oxygen use, creates problems in T-cell pathways, posing significant challenges. Early findings suggest that treating Tc1s with a drug called Oligomycin boosts non-oxygen related metabolism and effector cytokine production, potentially addressing issues linked to tumour hypoxia.The main idea is that Oligo-treated Tc1s will target hypoxic regions, while untreated ones will tackle non-hypoxic areas. The collaboration between reprogrammed cells and traditional Tc1s is expected to clear tumours completely. The study will check how well Oligo-treated Tc1s survive in a low-oxygen setting, looking at viability and conducting cytotoxic assays. Also, the therapeutic potential of Oligo-treated and traditional Tc1s will be compared in a mouse tumour model, focusing on their effectiveness in treating B16-gp33 tumours through ACT injections. Lastly, the spatial distribution of Tc1s in the Tumor Microenvironment will be studied, exploring the impact of metabolic intervention on therapy effectiveness using fluorescent immunohistochemistry. This research aims to optimize ACT by tweaking Tc1 cell metabolism, providing a new way to handle tumour hypoxia. The proposed study lays the groundwork for better cancer treatment, aiming to understand the potential of Oligo-treated Tc1s in ACT thoroughly.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
505954
Name
Coppens Kieran R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Metabolic Manipulation of Tc1 CD8 Cells for Enhanced Immunotherapy Against Tumour Hypoxia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy (Act); Cancer; Cd8 T Cells; Combination Therapy; Fluorescent Immunohistochemistry; Glycolytic Metabolism; Immunotherapy; Metabolic Manipulation; Mouse Tumour Model; Tumour Hypoxia
Abstract
Adoptive Cell Therapy (ACT) is a promising frontier in cancer treatment, harnessing the patient's own T cells for personalized therapeutic interventions. However, challenges persist, such as low oxygen in the tumour microenviroment prompting the need for interventions to improve outcomes. Tc1 CD8 cells, activated during viral or cancer related immune responses, have strong anti-tumor traits which can be crucial for ACT success. Tumour hypoxia, caused by poor blood supply and rapid oxygen use, creates problems in T-cell pathways, posing significant challenges. Early findings suggest that treating Tc1s with a drug called Oligomycin boosts non-oxygen related metabolism and effector cytokine production, potentially addressing issues linked to tumour hypoxia.The main idea is that Oligo-treated Tc1s will target hypoxic regions, while untreated ones will tackle non-hypoxic areas. The collaboration between reprogrammed cells and traditional Tc1s is expected to clear tumours completely. The study will check how well Oligo-treated Tc1s survive in a low-oxygen setting, looking at viability and conducting cytotoxic assays. Also, the therapeutic potential of Oligo-treated and traditional Tc1s will be compared in a mouse tumour model, focusing on their effectiveness in treating B16-gp33 tumours through ACT injections. Lastly, the spatial distribution of Tc1s in the Tumor Microenvironment will be studied, exploring the impact of metabolic intervention on therapy effectiveness using fluorescent immunohistochemistry. This research aims to optimize ACT by tweaking Tc1 cell metabolism, providing a new way to handle tumour hypoxia. The proposed study lays the groundwork for better cancer treatment, aiming to understand the potential of Oligo-treated Tc1s in ACT thoroughly.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Coppens, Kieran R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~